LeMaitre Vascular Coverage Initiated at Roth Capital (LMAT)
Analysts at Roth Capital initiated coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report issued to clients and investors on Thursday, AnalystRatings.Net reports. The firm set a “buy” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of LeMaitre Vascular from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, October 1st. They now have a $7.80 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of LeMaitre Vascular from $9.50 to $10.50 in a research note to investors on Wednesday, July 31st.
LeMaitre Vascular (NASDAQ:LMAT) opened at 6.73 on Thursday. LeMaitre Vascular has a 52 week low of $5.69 and a 52 week high of $7.19. The stock has a 50-day moving average of $6.77 and a 200-day moving average of $6.53. The company has a market cap of $102.7 million and a P/E ratio of 35.42.
LeMaitre Vascular, Inc (NASDAQ:LMAT) is a provider of medical devices and implants for the treatment of peripheral vascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.